リポジストロフィー
参考

↑  Phan J, Reue K (January 2005). “Lipin, a lipodystrophy and obesity gene”. Cell Metabolism 1 (1):  73-83. doi:10.1016/j.cmet.2004.12.002. PMID 16054046.
↑  “UCLA/VA Researchers discover fat gene”. 2018年10月6日時点のオリジナルよりアーカイブ。2017年6月15日閲覧。
↑  James, William D.; Berger, Timothy G. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 978-0-7216-2921-6
↑  Torrelo A, Patel S, Colmenero I, Gurbindo D, Lendínez F, Hernández A, López-Robledillo JC, Dadban A, Requena L, Paller AS (March 2010). “Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome”. Journal of the American Academy of Dermatology 62 (3):  489-495. doi:10.1016/j.jaad.2009.04.046. PMID 20159315.
1 2 3 4  Polyzos SA, Perakakis N, Mantzoros CS (2019). “Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement”. Metabolism: Clinical and Experimental 96:  66-82. doi:10.1016/j.metabol.2019.05.001. PMID 31071311.
1 2  Bruder-Nascimento T, Kress TC, Belin de Chantemele EJ (2019). “Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function”. F1000Research 8:  F1000 Faculty Rev-1756. doi:10.12688/f1000research.20150.1. PMC 6798323. PMID 31656583. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798323/.
↑  Physical and Biochemical Changes in HIV Disease Eric S. Daar, M.D. MedicineNet, Accessed 22 September 2007
↑  Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, Law M, Cooper DA (July 2002). “Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial”. JAMA 288 (2):  207-215. doi:10.1001/jama.288.2.207. PMID 12095385.
↑  John M, McKinnon EJ, James IR, Nolan DA, Herrmann SE, Moore CB, White AJ, Mallal SA (May 2003). “Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients”. Journal of Acquired Immune Deficiency Syndromes 33 (1):  29-33. doi:10.1097/00126334-200305010-00005. PMID 12792352.
↑  Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, Mungai L, Oral EA, Patni N, Rother KI, von Schnurbein J, Sorkina E, Stanley T, Vigouroux C, Wabitsch M, Williams R, Yorifuji T (December 2016). “The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline”. The Journal of Clinical Endocrinology and Metabolism 101 (12):  4500-4511. doi:10.1210/jc.2016-2466. PMC 5155679. PMID 27710244. https://academic.oup.com/jcem/article/101/12/4500/2764979.
↑  Ajluni N, Meral R, Neidert AH, Brady GF, Buras E, McKenna B, DiPaola F, Chenevert TL, Horowitz JF, Buggs-Saxton C, Rupani AR, Thomas PE, Tayeh MK, Innis JW, Omary MB, Conjeevaram H, Oral EA (May 2017). “Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort”. Clinical Endocrinology 86 (5):  698?707. doi:10.1111/cen.13311. PMC 5395301. PMID 28199729. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395301/.
↑  “Type 1 familial partial lipodystrophy: understanding the Köbberling syndrome”. Endocrine 54 (2):  411–421. (November 2016). doi:10.1007/s12020-016-1002-x. PMID 27473102.
↑  Meral R, Ryan BJ, Malandrino N, Jalal A, Neidert AH, Muniyappa R, Akıncı B, Horowitz JF, Brown RJ, Oral EA (October 2018). “"Fat Shadows" From DXA for the Qualitative Assessment of Lipodystrophy: When a Picture Is Worth a Thousand Numbers”. Diabetes Care 41 (10):  2255-2258. doi:10.2337/dc18-0978. PMC 6150431. PMID 30237235. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150431/.
↑  Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A (February 2002). “Leptin-replacement therapy for lipodystrophy”. The New England Journal of Medicine 346 (8):  570-578. doi:10.1056/NEJMoa012437. PMID 11856796.
↑  “Myalepta | European Medicines Agency”. www.ema.europa.eu. 2019年1月8日閲覧。
↑  Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, Geary RS, Baker BF, Graham MJ, Crooke RM, Witztum JL (December 2014). “Targeting APOC3 in the familial chylomicronemia syndrome”. The New England Journal of Medicine 371 (23):  2200-2206. doi:10.1056/NEJMoa1400284. PMID 25470695.
↑  Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, Geary RS, Hughes SG, Viney NJ, Graham MJ, Crooke RM, Witztum JL, Brunzell JD, Kastelein JJ (July 2015). “Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia”. The New England Journal of Medicine 373 (5):  438-447. doi:10.1056/NEJMoa1400283. PMID 26222559. https://semanticscholar.org/paper/b8b4f0ae969760d3373ca1d9082abfee85fe16d9.
↑  “The BROADEN Study: A Study of Volanesorsen (Formerly ISIS-APOCIIIRx) in Patients With Familial Partial Lipodystrophy - Full Text View - ClinicalTrials.gov” (英語). https://clinicaltrials.gov/ct2/show/NCT02527343 2018年3月31日閲覧。
↑  “Welcome to Lipodystrophy United” (英語). www.lipodystrophyunited.org. 20 December 2014時点のオリジナルよりアーカイブ。14 February 2021閲覧。
↑  “Lipodystrophy UK” (英語). www.lipodystrophyuk.org. 2020年2月29日閲覧。
↑  Inc., Ionis Pharmaceuticals. “Akcea Therapeutics Supports World Lipodystrophy Day” (英語). www.prnewswire.com. 2018年3月31日閲覧。
↑  “Aegerion Pharmaceuticals Observes World Lipodystrophy Day – PM360” (英語). www.pm360online.com. 2018年3月31日閲覧。